Eccogene is a clinical stage biopharmaceutical company developing small molecule therapeutics for chronic cardiometabolic and inflammatory conditions. The company focuses on safer and more effective oral therapies that target obesity and its comorbidities.

Eccogene

Eccogene | 609 followers on LinkedIn. Unlocking the full potential of GLP-1-based therapy  | Eccogene is focused on building a pipeline of best-in-class small molecule therapeutics for chronic cardiometabolic and inflammatory conditions with the goal of improving care and expanding access to cost effective medicines for millions of patients worldwide. Since our inception, our team has been dedicated to discovering safer and more effective oral therapies that may be used alone or synergistically with a GLP-1 receptor agonist to treat conditions beyond obesity.

Among our core strengths is our team -- comprised of individuals with world-class expertise in translational research and small molecule discovery -- as well as our deep understanding of diabetes, weight loss and cardiometabolic disease pathways.

Advancing life sciences innovations

Tim Xiao, CFA, FRM

Co-founder and CEO at Eccogene Inc

Jingye Zhou

Chief Financial Officer at Eccogene

Glenn Reicin

Senior Director of Pharmaceutical Sciences, Formulation Development at Karyopharm Therapeutics

Wen Chen

That’s a wrap on ObesityWeek 2024! Thank you to The Obesity Society for organizing a fantastic forum where researchers from around the world came together to showcase the latest in obesity science. #OW2024

This afternoon, two posters featuring Phase 1 data on ECC5004/AZD5004 will be presented at The Obesity Society 's #OW2024 . These findings support the rapid clinical advancement of this candidate, with the first patients in the Phase 2b trials for obesity and type 2 diabetes already dosed.

Today marks the beginning of ObesityWeek 2024! The Eccogene team has arrived in San Antonio and is thrilled to join this premier international conference for obesity researchers and clinicians. Tomorrow, Phase 1 results with our oral small molecule GLP-1 receptor agonist, ECC5004/AZD5004, will be unveiled for the first time in a poster session at 2:30 PM CT. For those at the meeting, we hope to see you there. The Obesity Society #OW2024

We are pleased to announce that our partner AstraZeneca dosed the first patients in the two Phase 2 trials of ECC5004/AZD5004 for the treatment of obesity and type diabetes. For more information, click here: https://lnkd.in/d4SW3RmM

We are pleased to welcome Glenn Reicin as Chief Financial Officer. With over three decades of experience in the healthcare industry, Glenn has successfully led strategies for both private and public financings and has played an integral role in building infrastructures that support company growth and pipeline expansion. We look forward to his many contributions to Eccogene. Read more: https://lnkd.in/eWFRiZ6y

ECCO

COM:ECCOGENE

Eccogene